Available commercially as Allegra D®, fexofendine has been the drug of first choice for the symptomatic treatment of allergic manifestations, as a non-sedating antihistamine agent. It is an active and chiral metabolite of terfenadine, a drug whose production and trading was suspended due to adverse events. The aim of this project is to develop and to validate a method to be further applied in a stereoselective biotransformation study and thus assess the ability of fungi in biotransform the drug terfenadine into its active metabolite, and therefore, to propose a new way of obtaining this drug, preferably in its pure enantiomeric form. It is known that fungal biotransformation studies have been presented as a promising alternative to provide enantio reactions as well as the production of chiral compounds from racemic mixtures. For this purpose, will be employed miniaturized extraction techniques, such as hollow phase liquid phase microextraction or dispersive liquid-liquid microextraction. As analytical technique it will be employed high performance liquid chromatography or capillary electrophoresis.
News published in Agência FAPESP Newsletter about the scholarship: